Travere Therapeutics (TVTX) shares ended the last trading session 8.8% higher at $9.49. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 19.9% gain over the past four weeks.The company currently markets Filspari (sparsentan), which is approved for treating IgA nephropathy, a form of kidney disease. The drug has been witnessing solid uptake in the market so far, recording sales of $40 million in the first quarter of ...